2.95
price down icon30.09%   -1.27
after-market After Hours: 3.23 0.28 +9.49%
loading
Alaunos Therapeutics Inc stock is traded at $2.95, with a volume of 2.74M. It is down -30.09% in the last 24 hours and up +97.99% over the past month. Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
See More
Previous Close:
$4.22
Open:
$4.42
24h Volume:
2.74M
Relative Volume:
6.23
Market Cap:
$4.72M
Revenue:
-
Net Income/Loss:
$-36.46M
P/E Ratio:
-1.2292
EPS:
-2.4
Net Cash Flow:
$-30.20M
1W Performance:
+102.05%
1M Performance:
+97.99%
6M Performance:
+12.17%
1Y Performance:
-83.43%
1-Day Range:
Value
$2.90
$5.35
1-Week Range:
Value
$1.3137
$5.35
52-Week Range:
Value
$1.3137
$18.00

Alaunos Therapeutics Inc Stock (TCRT) Company Profile

Name
Name
Alaunos Therapeutics Inc
Name
Phone
(346) 355-4099
Name
Address
2617 BISSONNET ST, HOUSTON
Name
Employee
34
Name
Twitter
Name
Next Earnings Date
2024-12-12
Name
Latest SEC Filings
Name
TCRT's Discussions on Twitter

Compare TCRT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TCRT
Alaunos Therapeutics Inc
2.95 4.72M 0 -36.46M -30.20M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-04-22 Resumed Wells Fargo Overweight

Alaunos Therapeutics Inc Stock (TCRT) Latest News

pulisher
01:04 AM

Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

01:04 AM
pulisher
04:33 AM

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World

04:33 AM
pulisher
Mar 27, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World

Mar 27, 2025
pulisher
Jan 29, 2025

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology

Jan 29, 2025
pulisher
Jan 15, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World

Jan 15, 2025
pulisher
Jan 10, 2025

Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology

Jan 10, 2025
pulisher
Dec 24, 2024

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World

Dec 24, 2024
pulisher
Dec 13, 2024

TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com

Dec 13, 2024
pulisher
Nov 22, 2024

Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology

Nov 22, 2024
pulisher
Nov 15, 2024

Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Ziopharm: Q3 Earnings Snapshot - The Washington Post

Nov 14, 2024
pulisher
Nov 08, 2024

TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria

Nov 08, 2024
pulisher
Oct 28, 2024

TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com

Oct 28, 2024
pulisher
Oct 13, 2024

Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com

Oct 13, 2024
pulisher
Oct 11, 2024

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech

Oct 11, 2024
pulisher
Oct 11, 2024

Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 11, 2024

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance

Oct 11, 2024
pulisher
Oct 11, 2024

Precigen reclaims rights after terminating license agreement - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch

Oct 10, 2024
pulisher
Oct 10, 2024

Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com

Oct 10, 2024
pulisher
Oct 01, 2024

Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena

Oct 01, 2024
pulisher
Sep 26, 2024

AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology

Sep 26, 2024
pulisher
Sep 18, 2024

Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech

Sep 18, 2024
pulisher
Sep 11, 2024

Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology

Sep 11, 2024
pulisher
Aug 28, 2024

Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology

Aug 28, 2024
pulisher
Aug 23, 2024

VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology

Aug 23, 2024
pulisher
Aug 14, 2024

Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology

Aug 14, 2024
pulisher
Aug 07, 2024

Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology

Aug 07, 2024
pulisher
Jul 16, 2024

Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com

Jul 16, 2024
pulisher
Jul 11, 2024

XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena

Jul 11, 2024
pulisher
May 29, 2024

Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology

May 29, 2024
pulisher
Mar 27, 2024

Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology

Mar 27, 2024
pulisher
Mar 25, 2024

Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology

Mar 25, 2024
pulisher
Feb 01, 2024

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider

Feb 01, 2024
pulisher
Jan 30, 2024

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks

Jan 30, 2024
pulisher
Jan 29, 2024

TScan Therapeutics Appoints Jason A. Amello as Chief Financial Officer - citybiz

Jan 29, 2024
pulisher
Jan 25, 2024

Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology

Jan 25, 2024
pulisher
Jan 24, 2024

NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena

Jan 24, 2024
pulisher
Jan 23, 2024

Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology

Jan 23, 2024
pulisher
Jan 08, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace

Jan 08, 2024
pulisher
Jan 05, 2024

Avistone raises $140m to support drug research and development - Pharmaceutical Technology

Jan 05, 2024
pulisher
Jan 04, 2024

BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology

Jan 04, 2024
pulisher
Jan 03, 2024

Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology

Jan 03, 2024
pulisher
Dec 18, 2023

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN

Dec 18, 2023
pulisher
Dec 18, 2023

Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider

Dec 18, 2023
pulisher
Nov 23, 2023

Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology

Nov 23, 2023
pulisher
Nov 14, 2023

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance

Nov 14, 2023
pulisher
Nov 09, 2023

Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology

Nov 09, 2023
pulisher
Nov 01, 2023

AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology

Nov 01, 2023
pulisher
Oct 26, 2023

How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology

Oct 26, 2023
pulisher
Aug 16, 2023

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq

Aug 16, 2023

Alaunos Therapeutics Inc Stock (TCRT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):